Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Kim Linton

Kim Linton

MBChB, MRCP, PhD, FRCP

University of Manchester

The encouraging early results of NX-5948, a novel BTK degrader, in patients with R/R CLL and NHL

The encouraging early results of NX-5948, a novel BTK degrader, in patients with R/R CLL and NHL

Kim Linton • 2 Jul 2024

PETReA: evaluating PET-adapted maintenance therapy approaches for patients with follicular lymphoma

PETReA: evaluating PET-adapted maintenance therapy approaches for patients with follicular lymphoma

Kim Linton • 1 Jun 2023

The changing landscape of BTK inhibitor therapy in patients with MZL

The changing landscape of BTK inhibitor therapy in patients with MZL

Kim Linton • 1 Jun 2023

MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma

MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma

Kim Linton • 18 May 2023

REFRACT: standard chemoimmunotherapy versus novel agents in R/R follicular lymphoma

REFRACT: standard chemoimmunotherapy versus novel agents in R/R follicular lymphoma

Kim Linton • 25 Apr 2023